Abstract
Ribosome-inactivating proteins (RIPs) were first isolated over a century ago and have been shown to be catalytic toxins that irreversibly inactivate protein synthesis. Elucidation of atomic structures and molecular mechanism has revealed these proteins to be a diverse group subdivided into two classes. RIPs have been shown to exhibit RNA N-glycosidase activity and depurinate the 28S rRNA of the eukaryotic 60S ribosomal subunit. In this review, we compare archetypal RIP family members with other potent toxins that abolish protein synthesis: the fungal ribotoxins which directly cleave the 28S rRNA and the newly discovered Burkholderia lethal factor 1 (BLF1). BLF1 presents additional challenges to the current classification system since, like the ribotoxins, it does not possess RNA N-glycosidase activity but does irreversibly inactivate ribosomes. We further discuss whether the RIP classification should be broadened to include toxins achieving irreversible ribosome inactivation with similar turnovers to RIPs, but through different enzymatic mechanisms.
Keywords: BLF1, BPSL1549, Shiga toxins, abrin, analytical and therapeutic applications, biological weapon, eukaryotic protein synthesis inhibition, ricin, saporin, α-sarcin
Introduction
Since their discovery decades ago, ribosome-inactivating proteins (RIPs) have been of great scientific interest due to their importance in human health, as both pathogenic agents and therapeutics, but also due to their potential use in biological warfare and bioterrorism. In the past few years, a number of comprehensive reviews have been written on a variety of these subjects.1-6 RIPs form a family of well-characterized toxins, which specifically and irreversibly inhibit protein synthesis in eukaryotic cells by enzymatically altering the 28S rRNA of the large 60S ribosomal subunit. Most are produced by plants and are thought to represent a defense mechanism against viral or parasitic attackers. Notable examples of plant-derived RIPs include ricin, abrin, and saporins.2,4 Other RIPs such as the Shiga toxins3,5 are instead produced as virulence factors by pathogenic bacteria in order to aid their survival and replication in host organisms. Injection, inhalation or ingestion of some of these toxins (e.g., ricin, abrin, and Shiga toxins) can be lethal even in small doses and triggers irreversible inhibition of host cellular protein synthesis accompanied by acute necrosis of affected tissues and organs. Underlining their potency as pathogenic agents, ricin has been classified as a potential category B biological warfare agent and a likely source of bioterrorism.7
Over a hundred RIPs have been isolated from various plants and bacteria with varying degrees of toxicity. These RIPs have been subdivided into two or three broad categories, with the two-category classification currently prevailing.1,8 In this classification type 1 RIPs are monomeric proteins of approximately 30 kDa which possess RNA N-glycosidase enzymatic activity. In contrast type 2 RIPs are composed of an A-chain with RNA N-glycosidase activity associated to one or several B-chain(s) of approximately 35 kDa.5,8-10 The B-subunit is a lectin-like peptide that has strong affinity for sugar moieties displayed on the surface of cells and helps promote translocation through the plasma membrane. As a consequence, type 2 RIPs generally tend to be more toxic than their type 1 counterparts, though this is not always the case since a number of type 2 RIPs (RCA120, Cinnamonin, Ebulin1/r1/r2, Nigrin b, SNA I, SNLRP, IRA b/r) display little or no toxicity despite possessing a lectin-like domain.11
The RIP family of toxins was originally described as sharing biochemical properties that lead to irreversible inactivation of eukaryotic protein synthesis by an enzymatic mechanism of action which leads to the abolition of the interaction between the large 60S ribosomal subunit and translation elongation factor 2.12,13 Toxic RIPs act at low doses because their catalytic activities allow complete inactivation of ribosomes and protein synthesis at a less-than-equimolar ratio to their substrate. RIPs display rRNA N-glycosidase activity (EC 3.2.2.22) and depurinate 28S rRNA by cleaving the bond between adenine and ribose in the exposed sarcin–ricin loop of the molecule14,15 thus preventing recruitment of translation elongation factors and subsequent protein synthesis. Other factors, such as a group of endonucleases isolated from fungi termed ribotoxins also trigger an irreversible inactivation of protein synthesis but through direct cleavage of the 28S rRNA rather than specific depurination. On this basis, they fit the criteria for being RIP family members, but there is controversy as to whether they should be considered true RIPs under the current classification system.16 In addition to the classification challenges presented by the fungal ribotoxins, a recently characterized bacterial toxin known as Burkholderia lethal factor 1 (BLF1) also shares many of the biological properties of RIPs but does not possess RNA N-glycosidase activity. This factor triggers accumulation of 80S initiating-ribosome species by a different enzymatic mechanism causing a drastic reduction in actively translating polysomes, and an irreversible stalling of translation prior to elongation.17,18
In this review, we compare the properties and potential applications of several well-characterized RIPs (ricin/abrin, Shiga toxins, and saporins) with those of the fungal ribotoxins and the bacterial toxin BLF1. In addition, we review the standing of non-RNA N-glycosidase ribosome inactivators within the current classification system, and ask whether the definition of a RIP should revert to a broader description which would take into account all enzymatic activities that irreversibly prevent translation elongation from occurring.
Ricin and Abrin (Plant Type 2 RIPs)
Ricin and abrin are among the best-characterized RIP family members and can be extracted from the seeds of Ricinus communis (castor bean plant) and Abrus precatorius (jequirity pea) respectively.19 Typical pathological symptoms of exposure to plant type 2 RIPs include abdominal pain, vomiting, diarrhea leading to fluid loss, electrolyte imbalance, and dehydration. Postmortem features include characteristic hemorrhagic intestinal lesions and histology which is consistent with localized cellular apoptosis and tissue necrosis.20
There have been other highly toxic type 2 RIP isolated from plants, including Modeccin, Pulchellin, Mistletoe lectin I, and Volkensin, but these will not be covered in this review, which focuses on comparing archetypal members of the RIP family with other potent inhibitors of cellular protein synthesis such as the α-sarcin and BLF1 toxins. The first recorded isolation of ricin was by the German scientist H Stillmark in 1888 during his doctoral work. The same research group, headed by the pioneering toxicologist R Kobert, also identified abrin as being a toxic protein. Early experiments in which the two purified proteins were tested on blood led to their classification as agglutination factors (aka agglutinins) since they induced the clumping of erythrocytes and the precipitation of serum-soluble proteins. Originally this agglutination was thought to be the cause of their toxicity but later work by P Ehrlich in 1891 hinted that this might not be the case. Ehrlich suggested that to be able to work the toxins needed to be fixed in tissue and hypothesized that the protein might consist of a binding region, named “haptophore”, and a toxin part, termed “toxophore”. When the crystal structures of both proteins were solved his hypothesis was shown to be remarkably close to the truth.21,22 Both proteins are heterodimers consisting of two disulfide-linked polypeptides, known as the A-chain and B-chain, which have distinct functions.8-10 The catalytic A-chain resembles Ehrlich’s toxophore while the lectin-like B-chain neatly fits the requirements of his haptophore.
Prior to the solving of its structure, ricin was shown to be a potent inhibitor of protein synthesis in intact metazoan cells23 as well as in cell-free systems.24,25 Since this inhibition was achieved with concentrations which were sub-stoichiometric to the number of ribosomes present, the mechanism of toxicity was assumed to be enzymatic in nature.25 Here, the significance of the A-chain becomes apparent since it possesses enzymatic ability in the form of RNA N-glycosidase activity. Investigation of this activity revealed that the enzyme specifically acted on an extended loop near the 3′ end of 28S rRNA in the eukaryotic ribosome14,15 providing a direct link between the function and the observed cellular effects. The glycosidase enzyme depurinates rRNA cleaving the glycosidic bond of a single adenine residue in the exposed loop (A4324 in rat liver). This leads to loss of the adenine base but not direct cleavage of the RNA chain. Instead it is thought that the RNA is left susceptible to hydrolysis and may be cleaved by cellular lyases.26 Subsequently, this mechanism has been found to be the same or very similar in many other RIPs with the shared site of action becoming known as the sarcin–ricin loop. Significantly, this loop is required for recruitment of factors needed for translation elongation,12 meaning even small disruptions to its structure have severe effects on protein synthesis. Remarkably a single molecule of either ricin or abrin is able to inactivate over a thousand ribosomes per minute,27,28 effectively leaving cells unable to assemble new ribosomes quickly enough to remain viable. However, as potent as it may be, the presence of an RNA N-glycosidase domain alone is not enough to explain the extreme toxicity of ricin and abrin, with LD50 = 8.0 µg/kg and LD50 = 2.8 µg/kg respectively in mice.1 To have that level of toxicity they must also have an effective way of crossing the plasma membrane and entering host cells to mediate their harmful effects. For this to occur an RNA N-glycosidase domain is not sufficient, a second functional domain is required. This second domain is the B-chain and is the defining feature of plant-derived type 2 RIPs. The B-chain belongs to a family of carbohydrate-binding proteins called lectins.9,10 These proteins exhibit highly specific binding to sugar moieties within a larger carbohydrate or as part of glycoprotein/glycolipid molecules. In the case of ricin/abrin their lectin-domains exhibit binding specificity for galactose and/or N-acetyl-galactosamine or less frequently N-acetyl-neuramic acid.29 It is this property of lectins that confers their haemagglutinating ability, allowing them to recognize carbohydrate groups displayed on the surface of erythrocytes, bind to them, and cause clumping of the blood cells. Most cells are covered in millions of potential binding sites for ricin/abrin in the form of terminal galactose residues on glycoproteins/glycolipids. Once bound, the toxins are absorbed into the cell by endocytosis either via clathrin-dependent30 or clathrin-independent31 mechanisms and are directed to early endosomal vesicles. The majority of the toxin molecules are then either transported to lysosomes for proteolytic degradation or recycled to the cell surface.4 However, around 5% of the toxin is able to find its way into the trans-Golgi network (TGN)32 and it is from this pool that the active toxin is eventually produced. The importance of this transport to the TGN is underlined by the observation that cells resistant to ricin show impaired endosome-to-Golgi transport at low temperature.33 Exactly what happens to ricin when it reaches the TGN is not fully understood but it is known that it is moved via retrograde transport through the Golgi stack and into the endoplasmic reticulum (ER). It has been hypothesized that this may be achieved through a number of routes34 and may be mediated by interactions between the B-chain and galactosylated substrates.35 Once in the ER lumen the remaining toxin, or at least the A-chain portion, is then translocated to the cytoplasm.36,37 It has been suggested that the A- and B-chains are separated in the ER through reduction of their disulphide bonds38 and that this in turn allows the A-chain to be retro-translocated to the cytoplasm through a pathway usually reserved for disposal of misfolded cellular proteins.39 While a large proportion of toxin directed down this route (known as the ER-associated protein degradation or ERAD pathway) is ubiquitinated and degraded by the proteasome upon arrival in the cytoplasm, a small fraction is able to escape this surveillance and bind to its ribosomal target. It is thought that the differences in toxicity of type 2 RIPs can at least in part be explained by their varying success in avoiding ERAD degradation. A diagram summarizing toxin uptake and action is presented in Figure 1.
Figure 1. Mechanisms of cellular entry and actions of RIPs. Shiga toxins are delivered into the cell after the B-chain binds globotriaosylceramide (Gb3) to stimulate clathrin-dependent/independent endocytosis. Upon reaching the Golgi the A-chain is cleaved by the protease Furin. Ricin is delivered into the cell after the binding of the lectin-like B chain to glycoproteins/glycolipids and clathrin-dependent/independent endocytosis. After retrograde translocation from the Golgi to the ER the A- and B-chains of ricin and Shiga toxins are separated. Saporin is delivered into the cytoplasm via a clathrin-dependent mechanism of uptake aided by saponins. Shiga toxins, ricin and saporin all inhibit translation using RNA N-glycosidase to depurinate 28S rRNA at the same adenine residue (A4324). Alpha-sarcin enters the cell via pinocytosis and cleaves the phosphodiester bond between G4325 and A4326. BLF1 is delivered into the cytoplasm via an intra-cellular pathogenic bacterium and deamidates the translation initiation factor eIF4A inactivating its RNA-helicase activity leading to inactivation of initiating ribosomes.
While the defining feature of both ricin and abrin is their ability to inhibit de novo protein synthesis they also display other properties that contribute to cytotoxicity. For over 20 years there have been reports of RIP-induced apoptosis in affected cells.40 It was initially assumed that ricin/abrin-induced apoptosis would be exclusively mediated by the ribotoxic stress response, however in the intervening years a number of different pathways have been implicated.41 The most prominent examples are the induction of DNA damage through removal of adenine from DNA42 and activation of the mitochondrial pathway of cell death.43 Furthermore, it has been demonstrated that both ricin and the Shiga toxins inhibit resolution of H2O2-induced DNA lesions, potentially through direct interaction with the repair machinery.44 Interestingly there have also been reports of an apoptotic pathway that is A-chain independent and therefore not connected to the inhibition of protein synthesis.45 It has been hypothesized that this may involve the B-chain bringing together pro-apoptotic receptors at the cell surface.
Shiga and Shiga-Like Toxins (Bacterial Type 2 RIPs)
While almost all type 2 RIPs have so far been isolated from plant species, the Shiga and Shiga-like toxins are instead produced by gram-negative bacterial species. In the late 19th century Kiyoshi Shiga, a Japanese physician and bacteriologist, was investigating the cause of dysentery during a large epidemic in which over 90 000 cases were recorded and the mortality rate was as high as 30%.46 During this epidemic Shiga isolated a gram-negative bacillus bacterium from the stool of patients, which he termed Bacillus dysenteriae. This bacterium when fed to dogs led to the onset of diarrhea and toxic factors were found in autolysates of the bacterial cultures. This bacterium and the virulence factor it produces were later confirmed to be one of the major causes of bacillary dysentery and were renamed Shigella dysenteriae and Shiga toxin in honor of his discovery. While early work suggested Shiga toxin to be a neurotoxin since it caused limb paralysis when injected into animal models, by the 1970s a relevant gastrointestinal effect of the protein had been established.47 Soon after it was found that isolates from certain strains of Escherichia coli contained a factor that was able to kill Vero cells in vitro.48 These factors were referred to as verotoxins and the bacteria that produced them were termed Verotoxin-producing E. coli (VTEC). However, this definition was subsequently altered a few years later when O’Brien and colleagues identified strains of E. coli with isolates that contained a toxin related to Shiga49 that caused hemorrhagic colitis and infantile diarrhea.50 When it was shown that the verotoxin and Shiga-like toxins could both be neutralized by antibodies to the original Shiga toxin, researchers soon realized they were working with the same strains51 and led to the strains being reclassified as Shiga-like toxin-producing E. coli (STEC). The fact that remarkably similar toxins were present in two unrelated bacterial species strongly suggested the horizontal transfer of a mobile genetic element. This was proven to be the case when it was found that the Shiga toxins (Stxs) were encoded by genes within the genomes of working or non-functional lamboid bacteriophages.50 These Stx-phages are able to integrate into the host chromosome and are defined by the presence of the Stx-operon, comprised of the genes necessary for toxin production. Apart from this element, the Stx-phages display a high degree of heterogeneity and mosaicism52,53 most likely due to recombination events caused by the presence of multiple phages within the same bacterium.54 Significantly, it has been shown that Stx-phages infect other commensal bacteria in the gut, effectively recruiting them to aid in toxin production.55,56 This poses problems during outbreaks of Shiga-related illness as symptoms and severity can vary between cases infected with the same strain.
As revealed by X-ray crystallography, all Shiga toxins are of the AB5 protein family57,58 and are composed of subunits with functions analogous to those of the classic type 2 RIPs identified in plants. A catalytic monomer, termed StxA, is non-covalently associated with 5 surrounding B-fragments that form the B-subunit StxB. Both peptides are synthesized and secreted into the bacterial periplasm where they are assembled into a holotoxin59 with StxB resembling a doughnut-shaped pentamer into which the carboxyl terminus of StxA sits. In terms of protein sequence there is remarkable similarity between the prototype Shiga toxin (Stx) from S. dysenteriae and the major Shiga-like toxins found in STECs (Stx1 and Stx2). Stx and Stx1 are the most similar, sharing identical B-fragments and differing by a single amino acid in the A-subunit.60,61 Interestingly, Stx2 only shares 56% protein homology with Stx/Stx1 despite having an identical mechanism of action.62
As mentioned, the Stx proteins can be thought of as analogous to the plant toxins ricin and abrin and this is reflected in both their function and mechanism of action. As with ricin/abrin the A-subunit provides the RNA N-glycosidase activity while the B-subunit displays high affinity for specific cell surface sugar moieties. Remarkably, the RNA N-glycosidase activity is identical to that found in ricin/abrin with depurination of the 28S rRNA sarcin–ricin loop occurring at exactly the same adenine residue (A4324).63,64 Again, removal of this adenine prevents binding of elongation factors and associated amino-acyl tRNAs and results in stalling of protein synthesis at the elongation stage.65,66 Like all classic type 2 RIPs, the Shiga toxins are also able to gain entry into intact cells, and this is mediated by the StxB portion of the assembled protein. Each B-fragment contains three distinctive binding sites for the trisaccharide side chain of glycosphingolipid globotriaosylceramide (Gb3), a glycolipid displayed on the surface of many mammalian cells,67,68 and binding to this group leads to the internalisation of the toxin by endocytosis. The reliance on Gb3 for Stx protein entry was emphasized by elegant experiments in which Stx resistant cells were made susceptible to the toxin by incorporation of Gb3 into the plasma membrane69 or where previously susceptible cells were rendered immune through deletion of the Gb3 synthase gene.70 The only known exception to this Gb3-dependence occurs in porcine models where the Stx2 variant Stx2e exhibits specific affinity for globotetraosylceramide (Gb4).71,72 In general terms the mechanisms of endocytosis of the Shiga toxins and their transport through the Golgi and ER are very similar to those previously described for ricin/abrin and therefore will not be discussed in detail.73,74 In common with the diphtheria and Pseudomonas toxins75 Shiga toxins must be cleaved by the membrane-associated protease furin in order to become functional as toxins in the cytoplasm.76 Furin cleaves StxA at a protease-sensitive loop toward the C-terminus at an alanine moiety between Arg-251 and Met-253 to produce a large catalytic A1 fragment (~27.5 kDa) and a small StxB-associated A2 fragment (~4.5 kDa).76 The A1 and A2 fragments remain associated with each other through a disulphide link which must be reduced after retrograde transportation to the ER lumen in order to free the catalytic A1 fragment for transfer to the cytoplasm.77,78 Again, like other type 2 RIPs, it is thought that transport to the cytoplasm is achieved through ERAD since Shiga toxins have been successfully co-immunoprecipitated with chaperone and translocon factors associated with this pathway.79,80 Significantly, approximately only 4% of molecules make it through all the transportation processing events that allow them to become mature toxins capable of RIP activity in the cytoplasm81 (Fig. 1).
Outside of their RIP function the Shiga toxins activate various signaling pathways within host cells which lead to apoptosis by mechanisms similar to those affected by ricin/abrin82,83 including those related to DNA damage.42,44 Activation of the ribotoxic stress response via one of the three major cellular MAPK cascades represents the most commonly activated pathway and happens as a direct consequence of ribosome inactivation.84 Significantly, activation of this response has also been linked to release of cytokines that cause upregulation of the Gb3 receptor protein in neighboring cell types, thereby potentially sensitizing them to infection by the toxin.85 An additional way in which Shiga toxins are thought to induce programmed cell death is through an ER quality control measure known as the unfolded protein response (UPR). This is proposed to be triggered by transient unfolding of the A1 fragment prior to cytoplasmic translocation leading to stimulation of ER stress receptors with a subsequent release of Ca2+ ions and activation of cellular caspases.86 There is also evidence that the purified B-domain of Stx1 is able to stimulate ER stress-independent apoptosis in Burkitt’s lymphoma cells, potentially by cross-linking of Gb3 receptors at the cell surface.87,88
Saporins (Plant Type 1 RIPs)
So far this review has considered the type 2 RIPs, which, despite being the most extensively studied class only account for a small proportion of all known RIPs.8 The majority of RIPs discovered so far actually belong to type 1 and are mostly produced in plant species, with preferential distribution within particular families such as Caryophyllaceae, Cucurbitaceae, and Euphorbiaceae.8 While type 2 RIPs can be extremely toxic due to the presence of lectin-like B-chains and their ability to promote entry into target cells, the type 1 RIPs by comparison are much less harmful. This lack of toxicity is not due to them being poor ribosome inactivators, since they are potent inhibitors of translation in cell free systems.89 It is instead because they lack an efficient means of entering host cells.1 In fact type 1 RIPs in plants such as spinach90 and tomato2 can be consumed raw without posing any threat to health.
Many type 1 RIPs have been studied extensively, including gelonin, PAP, momordin, and trichosanthin. However, the best characterized and most widely utilized type 1 RIPs are the saporins which can be extracted from roots, leaves and seeds of Saponaria officinalis, commonly known as soapwort.91 In total, nine related RIPs with alkaline pI values have been isolated from soapwort. Saporin-6 is the most abundant and the form most commonly considered the archetypal saporin. The structure of saporin-6 is very similar to that of the A-chain of type 2 RIPs92 and it displays the universally conserved RNA N-glycosidase activity specific for A4324 of 28S rRNA.93,94 In addition saporins are extremely stable when exposed to a number of denaturing conditions.95 While the lack of a B-chain moiety means that saporins generally show low toxicity in most cells this is not always the case. There is conflicting evidence as to whether saporins can stimulate endocytosis by binding to the surface receptor α2-macroglobulin94,96 while a clathrin-dependent mechanism of uptake involving the detergent-like saponins (also produced in soapwort) has been proposed.97 Once internalized, saporin is trafficked to the cytoplasm through a different route to that of the ricin A-chain utilizing a Golgi-independent mechanism which does not require low pH for membrane translocation98 (Fig. 1). Because of the relative safety in handling saporins and their extreme stability they are extensively used as a therapeutic/research tool when conjugated to other biological molecules that target specific cell types.
Fungal Ribotoxins
Though plant-derived proteins make up the vast majority of proteins that inhibit protein synthesis, a handful have been isolated from fungal species, of which α-sarcin (henceforth referred to as sarcin) is the most famous.99 Sarcin is a monomeric protein secreted by the fungus Aspergillus giganteus that has been shown to inhibit protein synthesis in cell-free systems.100 More precisely, sarcin belongs to a family of fungal ribotoxins16,101 with specific RNA endonuclease activity centring on the sarcin–ricin loop of 28S rRNA.102 Despite targeting the same rRNA structure as the RNA N-glycosidase RIPs, sarcin and related ribotoxins destroy the function of ribosomes by a wholly unique mechanism. Instead of depurinating the rRNA through removal of A4324, the phosphodiester bond between G4325 and A4326 is cleaved.103 Just like depurination, this alteration disrupts the structure of the sarcin–ricin loop preventing recruitment of elongation factors essential for protein synthesis (Fig. 1). Structural studies on multiple ribotoxins revealed that sarcin, RNase T1, and RNase A shared a common catalytic mechanism and belong to the cycling class of ribonucleases.104 It was later shown that Arg-121 is essential for the RIP activity and cytotoxicity of sarcin since when this residue was replaced (while retaining protein conformation) both were abolished.105 Because of the disparity in enzymatic function between the ribotoxins and the classic N-glycosidase activity of RIPs, there is controversy in the field as to whether ribotoxins should be considered as true RIPs.16
Burkholderia Lethal Factor 1 (BLF1)
As described above, sarcin and the other fungal ribotoxins inactivate ribosomes using a mechanism that does not require depurination of the 28S rRNA. The recent discovery of the BLF1 toxin, which like the Shiga toxins before it, originates in pathogenic bacteria, represents a new addition to this group of RNA N-glycosidase independent ribosome inactivators.
The intracellular pathogen Burkholderia pseudomallei is the causative agent of melioidosis, a chronic and often fatal infectious disease which affects millions people across the world.106 The bacterium was isolated a century ago107 but the mechanisms by which it kills and/or remains dormant for decades within infected hosts still remain largely unknown. A breakthrough against melioidosis was made in 2011 when an international team of researchers lead by the Wilson and Rice groups from the University of Sheffield characterized the first lethal cytotoxic factor from B. pseudomallei which irreversibly inactivates host protein synthesis.17 This protein is thought to be the major cause of B. pseudomallei pathogenesis, though it is possible that other toxins also contribute to cell death/tissue necrosis given that the bacterium has a well-stocked arsenal of virulence factors.108
This lethal toxin was found to be encoded by a gene of unknown function systematically named BPSL1549 after sequencing of the B. pseudomallei genome in 2004.108 BPSL1549 toxin was subsequently renamed BLF1 for Burkholderia lethal factor 1.17,18,109 Comparison of the proteomes of B. pseudomallei and the non-pathogenic but related strain Burkholderia thailandensis revealed that 14 uncharacterized protein biomarkers were expressed in the extracts of the pathogenic strain.110 A structural program aimed at investigating some of these proteins led to the determination of the crystal structure of BPSL1549/BLF1 by the Rice group.17 Injection of the recombinant protein intramuscularly or through the intraperitoneal route kills exposed mice with 10 μg BLF1 plus adjuvant, or 100 μg BLF1 alone while transfection of BLF1 also kills mammalian cells lines, as well as macrophages. Potent cytotoxic effects are achieved with a concentration as low as 2.5 × 10−7 M.17 This is similar to concentrations described for RNA depurination by ricin which has a KM of 1–2 × 10−7 M.28 BLF1 was shown to be a deamidase enzyme which specifically deamidates Gln-339 of the eukaryotic translation initiation factor eIF4A inactivating its RNA-helicase activity.17 This RNA-helicase activity is thought to be required for unwinding secondary structures in the 5′ untranslated regions of circularized mRNA prior to the assembly of the large and small ribosome subunits and initiation of translation. The eIF4a factor has been shown to be essential for the recruitment of the 40S ribosomal subunit (and other initiation factors) to capped mRNA and remains associated to initiating ribosomal complexes during scanning prior to translation elongation.111-114 Significantly, while the action of BLF1 does not directly damage the ribosome, it is important to note that the BLF1-modified eIF4A factor cannot be recycled for new rounds of translation initiation as pre-initiating 80S ribosomal complexes are irreversibly stalled on mRNA molecules rendering them lost. This leads to a pronounced accumulation of stalled 80S ribosomes and a concomitant decrease in the number of polysomes measured in sucrose sedimentation experiments. Indeed, in cell-free systems affected by BLF1 exogenous recombinant eIF4A cannot be incorporated into the stalled ribosomes, further emphasizing the irreversible nature of the ribosome inactivation and the dominant negative effect of the BLF1-modified eIF4A on ribosome function.17
The catalytic turnover of BLF1 was determined to be around 700 substrate molecules per minute,17 a rate similar to the rRNA depurination catalyzed by ricin,27,28 suggesting that the high turnover of BLF1-dependant inhibition of protein synthesis leads to cell death when all functioning ribosomes in a cell are inactivated by modified eIF4A18,109 (Fig. 1).
RIPs as Potential Biological Weapons and Criminal Agents
In 1997, the US government designated several RIPs as “select agents” with the “potential to pose a severe threat to public health and safety”. Since then, Burkholderia pseudomallei, the related bacterium Burkholderia mallei, and several toxins, including ricin, were classified as category B biological warfare agents.7 Category B weapons are described as “agents with some potential for large-scale dissemination with resultant illness, but” which “generally cause less illness and death” than category A agents such as anthrax and botulinum.
Ricin was reported to be investigated by the US biological weapon program during World War I and II115,116 as well as Canada during World War II116 for utilization as weaponized toxic dust or coated onto bullets and anti-personnel mines, though it was never used in combat. This seems in part due to the fact that disease-producing spores of other biological agents such as Bacillus anthracis or Clostridium botulinum persist much longer in the environment than a purified protein such as ricin. Furthermore, it was assessed that several tons of ricin powder would be required to target urban populations making ricin unsuitable as a biological weapon of mass destruction.117 However, ricin continues to remain in the public consciousness mainly because of its potential for usage by terrorists/criminals in assassination plots or acts of terror, with this fear coming from the fact that it is relatively simple to isolate from an easily accessible source (castor bean plant). Famously, in 1978, ricin was used in the murder of a London-based Bulgarian dissident, Georgi Markov. Markov was a critic of the communist regime in Bulgaria and it is commonly accepted that the Bulgarian secret service assassinated him using a ricin capsule fired from the tip of an umbrella using compressed gas.117 Since then, ricin has continued to be used or attempted to be used for murder/intimidation in a number of plots, the latest high-profile incident being a ricin-laced letter sent to US president Barack Obama in April 2013. Because of these continuing concerns regarding the potential for ricin attacks significant efforts have been made to prepare for such events and contingencies have been put in place.118 This includes the development of effective vaccines such as RiVax™ from the biopharmaceutical company Soligenix Inc., which can immunize mice, rabbits, and humans against ricin exposure.119
The BLF1-producing pathogen, B. pseudomallei, easily grows outside a laboratory in most climates making it a prime candidate for utilization by terrorists.120 It can survive in distilled water for a number of years121 and infects almost all mammals122 and tomato plants123 raising concerns about its ease of storage/dissemination and the potential for long-term environmental contamination if used in an attack. No vaccine has yet been formulated despite many attempts.124 Precedence for the use of B. pseudomallei as a bio-weapon comes from the historical use of the closely related bacterium B. mallei. This bacteria is the causative agent of “glanders”, an equine disease contagious to humans that is very similar to melioidosis.125,126 It was the first biological weapon used during the American Civil War,127 and was utilized in World War I by the German army to deliberately contaminate livestock and humans.128,129 It has also been reported that the Soviet biological weapons program conducted field tests with B. mallei which inadvertently killed some of the researchers, and that the bacterium may have been used against the Mujahideen during the Afghanistan War in the late 1970s.130
Research and Therapeutic Applications
RIP family members have several practical applications ranging from benefits to agriculture to biomedical therapies as described recently in a review by F Stirpe.6 RIPs not only constitute potent molecular tools for studying translation but also have potential applications in the treatment of human disease since several inhibitors of protein synthesis have been used as anti-cancer agents including inhibitors of eIF4A.131,132 Since BLF1 is a potent inhibitor of eIF4A and exhibits high levels of cytotoxicity, it also represents a suitable candidate for investigation of anti-cancer properties.18,109 Immunotoxins built by conjugating an antibody recognizing a cancer cell-specific epitope to the A-chain of ricin seemed to be promising therapeutics following in vitro studies in tumor cell lines133 but have unfortunately shown less efficacy in vivo in mice or humans.134 In contrast, saporin-based immunotoxins have shown potent in vitro and in vivo anti-cancer activity against prostate cancer.135 Substance-P-conjugated saporins (SP-SAP) have also been developed as selective destroyers of neurons involved in pain transmission and may provide a method of treating pain in patients with chronic illnesses.136 Other type I and II RIPs from plants have shown antitumor activity both in vivo and in vitro on cancers from various tissues.4 However, current challenges involve finding specific and efficient methods of drug delivery as well as overcoming the instability of RIPs in circulating plasma. Chemical conjugation of RIPs to water-soluble polyethylene glycol polymers, which protect against proteolytic cleavage, significantly improves their half-lives while also reducing their immunogenicity.137 Another issue with the use of RIP-containing immunotoxins is the high immune response they trigger in treated subjects due to them being recognized as foreign proteins. Repeat doses lead to development of immunological memory which severely decreases the half-life, and therefore effectiveness, of the immunotoxins over time.6
RIPs have also served as molecular tools to selectively kill specific cell types in order to study their physiological or behavioral relevance. For example, a saporin-based immunotoxin was generated to target and kill rat cholinergic neurons in the basal forebrain to study their function in cognition and behavioral comportment.138 This in turn led to the discovery of an animal model mimicking Alzheimer disease for drug screening.138 The potential biotechnological and medical uses of saporin can be attributed to its unusually high resistance to proteolysis and denaturation in solutions containing up to 4 M urea or guanidine95as well as its relative safety in its unmodified form.
Concluding Remarks
RIPs can traditionally be sub-divided into two distinct classes based on their structure. Type 2 RIPs, which include the most potent toxins in the RIP family, are heterodimers comprising a catalytic RNA N-glycosidase A-domain linked by disulphide bonds to a lectin-like B-domain that promotes entry into target cells. Type 1 RIPs on the other hand consist only of the A-domain and are generally less toxic as a result. Both classes inactivate ribosomes using a common mechanism in which the RNA N-glycosidase domain depurinates a specific adenine (A4324) within the sarcin–ricin loop of the 28S rRNA molecule leading to structural disruption and subsequent failure to recruit translation elongation factors. However, there are other proteins that can achieve the same end result as classical RIPs without utilizing an RNA N-glycosidase-based mechanism. The fungal ribotoxins, including prominent members such as sarcin, RNase T1, and RNase A, are able to irreversibly inactivate protein synthesis by directly cleaving the phosphodiester bond between G4325 and A4326 of the sarcin–ricin loop. Just like depurination this alters the secondary structure and prevents translation elongation from occurring. In common with the ribotoxins, the newly identified bacterial toxin BLF1 is also able to affect an irreversible inactivation of protein synthesis using an enzymatic mechanism which does not rely on RNA N-glycosidase activity. Instead of modifying rRNA, BLF1 functions as a deamidase enzyme, specifically acting on the translation initiation factor eIF4A and causing a Gln to Glu deamidation which abolishes its RNA helicase activity. Ablation of this activity prevents eIF4A functioning correctly and causes the modified eIF4A to act as a non-recyclable dominant negative factor when associated with 80S-initiating ribosomes. This leads to accumulation of 80S initiating-ribosome species and prevention of translation elongation, leading to an eventual inactivation of cellular protein synthesis when all active ribosomes have been stalled.
Given their disparate catalytic functions the ribotoxins and BLF1 unsurprisingly show no sequence or structural similarity to classical type 1 or 2 RIPs (Fig. 2). However, the cytotoxicity of BLF1 is comparable to that conferred by the highly toxic type 2 RIPs such as ricin or abrin despite being only composed of a single catalytic polypeptide chain. BLF1 also lacks the lectin-like domain required for efficient target cell entry. However, it does not need to be able to provide its passage into host cytoplasm to achieve its high toxicity as the bacterium that produces BLF1, B. pseudomallei, is an intracellular pathogen.
Figure 2. Ribbon representations of the X-ray crystallography structures of type 1/2 RIPs and BLF1. Ricin, saporin, and Shiga toxin Stx2 have N-glycosidase activity that cleaves the 28S rRNA while BLF1 catalyzes the deamidation of the eIF4A initiation translation factor. (A) Structure of Ricin A-chain in complex with the cyclic tetranucleotide inhibitor; PDB ID code 3HIO.139 (B) Structure of saporin in complex with the cyclic tetranucleotide inhibitor; PDB ID code 3HIW.139 (C) Structure of Shiga-like Stx2 A-chain from Escherichia coli in complex with adenine; PDB ID code 2GA4.140 Red-labeled residues Tyr-80, Tyr-123, and Arg-180 in the active site of ricin A-chain are equivalent in saporin and Stx2 (Tyr-73, Tyr-123, Arg-177 and Tyr-77, Tyr-114, Arg-170, respectively).92,139-141 The catalytic water molecule and crystallized inhibitors within the active sites are not represented for improving clarity. In contrast, Glu-177 of Stx2 is not conserved with the Glu-177/174 in the active sites of ricin and saporin respectively. Glutamate residues are labeled in blue. (D) Structure of BLF1, PDB ID code 3TU8.17 The primary sequence Leu-91 Ser-92 Gly-93 is (cyan) is conserved in the carboxyl-terminal domain of CNF1 along with Cys-94. Residues forming the catalytic triad of BLF1 (Thr-88, Cys-94, and His-106) are shown in red. Both the tertiary structure and catalytic site of BLF1 are different from type 1 and 2 RIPs represented in (A–C).
As noted earlier, ribotoxins and BLF1 are able to impose an irreversible inhibition of protein synthesis where active elongation no longer occurs. This would place them within early definitions of RIPs which were described as proteins that could irreversibly inactivate eukaryotic ribosomes in a catalytic fashion preventing recruitment of elongation factor(s).12,13 More recently, the description of RIPs has become restricted to proteins which exhibit the aforementioned properties but also have RNA N-glycosidase activity and has led to inconsistencies regarding the status of proteins such as the ribotoxins and now BLF1. With this in mind we ask whether a return to more inclusive description of RIPs would be beneficial. It is clear that the ribotoxins and BLF1 do not belong within the classical RIP family, but because the cellular consequences of their activities are identical to those of bona fide RIPs (i.e., a block of protein synthesis), it seems appropriate that they be more formally recognized as unconventional members of the RIP family. It is also very likely that more members of both the ribotoxin and deamidase classes of ribosome inactivators will be identified in the future. This is particularly relevant to the deamidase class since B. pseudomallei has been shown to have a remarkably fluid genome,108 suggesting that BLF1 and a number of its other virulence factors may have been acquired horizontally through conjugation and/or transduction meaning there are likely to be similar toxins waiting be discovered in other bacterial species.
In conclusion, RIPs could be described as any protein factor which irreversibly inactivates protein synthesis in an enzymatic manner thereby preventing translation elongation from occurring. This would encompass all the proteins described in this review and be broad enough to accommodate novel toxins and/or enzymatic mechanisms which achieve a similar cellular outcome. The two-division system for classical RNA N-glycosidase RIPs could remain while an extra provision could be created for unconventional RIPs which catalyze ribosome inactivation in an RNA N-glycosidase-independent manner.
Disclosure of Potential Conflicts of Interest
The authors declare that no conflict of interest exists.
Footnotes
Previously published online: www.landesbioscience.com/journals/virulence/article/26399
References
- 1.Stirpe F, Battelli MG. Ribosome-inactivating proteins: progress and problems. Cell Mol Life Sci. 2006;63:1850–66. doi: 10.1007/s00018-006-6078-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Barbieri L, Polito L, Bolognesi A, Ciani M, Pelosi E, Farini V, Jha AK, Sharma N, Vivanco JM, Chambery A, et al. Ribosome-inactivating proteins in edible plants and purification and characterization of a new ribosome-inactivating protein from Cucurbita moschata. Biochim Biophys Acta. 2006;1760:783–92. doi: 10.1016/j.bbagen.2006.01.002. [DOI] [PubMed] [Google Scholar]
- 3.Johannes L, Römer W. Shiga toxins--from cell biology to biomedical applications. Nat Rev Microbiol. 2010;8:105–16. doi: 10.1038/nrmicro2279. [DOI] [PubMed] [Google Scholar]
- 4.Puri M, Kaur I, Perugini MA, Gupta RC. Ribosome-inactivating proteins: current status and biomedical applications. Drug Discov Today. 2012;17:774–83. doi: 10.1016/j.drudis.2012.03.007. [DOI] [PubMed] [Google Scholar]
- 5.Bergan J, Dyve Lingelem AB, Simm R, Skotland T, Sandvig K. Shiga toxins. Toxicon. 2012;60:1085–107. doi: 10.1016/j.toxicon.2012.07.016. [DOI] [PubMed] [Google Scholar]
- 6.Stirpe F. Ribosome-inactivating proteins: from toxins to useful proteins. Toxicon. 2013;67:12–6. doi: 10.1016/j.toxicon.2013.02.005. [DOI] [PubMed] [Google Scholar]
- 7.Rotz LD, Khan AS, Lillibridge SR, Ostroff SM, Hughes JM. Public health assessment of potential biological terrorism agents. Emerg Infect Dis. 2002;8:225–30. doi: 10.3201/eid0802.010164. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Stirpe F. Ribosome-inactivating proteins. Toxicon. 2004;44:371–83. doi: 10.1016/j.toxicon.2004.05.004. [DOI] [PubMed] [Google Scholar]
- 9.Olsnes S, Pihl A. Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis. Biochemistry. 1973;12:3121–6. doi: 10.1021/bi00740a028. [DOI] [PubMed] [Google Scholar]
- 10.Olsnes S, Pihl A. Isolation and properties of abrin: a toxic protein inhibiting protein synthesis. Evidence for different biological functions of its two constituent-peptide chains. Eur J Biochem. 1973;35:179–85. doi: 10.1111/j.1432-1033.1973.tb02823.x. [DOI] [PubMed] [Google Scholar]
- 11.Barbieri L, Ciani M, Girbés T, Liu W-Y, Van Damme EJM, Peumans WJ, Stirpe F. Enzymatic activity of toxic and non-toxic type 2 ribosome-inactivating proteins. FEBS Lett. 2004;563:219–22. doi: 10.1016/S0014-5793(04)00286-8. [DOI] [PubMed] [Google Scholar]
- 12.Montanaro L, Sperti S, Mattioli A, Testoni G, Stirpe F. Inhibition by ricin of protein synthesis in vitro. Inhibition of the binding of elongation factor 2 and of adenosine diphosphate-ribosylated elongation factor 2 to ribosomes. Biochem J. 1975;146:127–31. doi: 10.1042/bj1460127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Stirpe F. On the action of ribosome-inactivating proteins: are plant ribosomes species-specific? Biochem J. 1982;202:279–80. doi: 10.1042/bj2020279. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Endo Y, Mitsui K, Motizuki M, Tsurugi K. The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. J Biol Chem. 1987;262:5908–12. [PubMed] [Google Scholar]
- 15.Endo Y, Tsurugi K. RNA N-glycosidase activity of ricin A-chain. Mechanism of action of the toxic lectin ricin on eukaryotic ribosomes. J Biol Chem. 1987;262:8128–30. [PubMed] [Google Scholar]
- 16.Lacadena J, Alvarez-García E, Carreras-Sangrà N, Herrero-Galán E, Alegre-Cebollada J, García-Ortega L, Oñaderra M, Gavilanes JG, Martínez del Pozo A. Fungal ribotoxins: molecular dissection of a family of natural killers. FEMS Microbiol Rev. 2007;31:212–37. doi: 10.1111/j.1574-6976.2006.00063.x. [DOI] [PubMed] [Google Scholar]
- 17.Cruz-Migoni A, Hautbergue GM, Artymiuk PJ, Baker PJ, Bokori-Brown M, Chang C-T, Dickman MJ, Essex-Lopresti A, Harding SV, Mahadi NM, et al. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A. Science. 2011;334:821–4. doi: 10.1126/science.1211915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hautbergue GM, Wilson SA. BLF1, the first Burkholderia pseudomallei toxin, connects inhibition of host protein synthesis with melioidosis. Biochem Soc Trans. 2012;40:842–5. doi: 10.1042/BST20120057. [DOI] [PubMed] [Google Scholar]
- 19.Olsnes S. The history of ricin, abrin and related toxins. Toxicon. 2004;44:361–70. doi: 10.1016/j.toxicon.2004.05.003. [DOI] [PubMed] [Google Scholar]
- 20.Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review. JAMA. 2005;294:2342–51. doi: 10.1001/jama.294.18.2342. [DOI] [PubMed] [Google Scholar]
- 21.Tahirov TH, Lu TH, Liaw YC, Chu SC, Lin JY. A new crystal form of abrin-a from the seeds of Abrus precatorius. J Mol Biol. 1994;235:1152–3. doi: 10.1006/jmbi.1994.1066. [DOI] [PubMed] [Google Scholar]
- 22.Weston SA, Tucker AD, Thatcher DR, Derbyshire DJ, Pauptit RA. X-ray structure of recombinant ricin A-chain at 1.8 A resolution. J Mol Biol. 1994;244:410–22. doi: 10.1006/jmbi.1994.1739. [DOI] [PubMed] [Google Scholar]
- 23.Lin JY, Chang YC, Huang LY, Tung TC. The cytotoxic effects of abrin and ricin on Ehrlich ascites tumor cells. Toxicon. 1973;11:379–81. doi: 10.1016/0041-0101(73)90037-8. [DOI] [PubMed] [Google Scholar]
- 24.Olsnes S, Pihl A. Ricin - a potent inhibitor of protein synthesis. FEBS Lett. 1972;20:327–9. doi: 10.1016/0014-5793(72)80098-X. [DOI] [PubMed] [Google Scholar]
- 25.Montanaro L, Sperti S, Stirpe F. Inhibition by ricin of protein synthesis in vitro. Ribosomes as the target of the toxin. Biochem J. 1973;136:677–83. doi: 10.1042/bj1360677. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ogasawara T, Sawasaki T, Morishita R, Ozawa A, Madin K, Endo Y. A new class of enzyme acting on damaged ribosomes: ribosomal RNA apurinic site specific lyase found in wheat germ. EMBO J. 1999;18:6522–31. doi: 10.1093/emboj/18.22.6522. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Olsnes S, Fernandez-Puentes C, Carrasco L, Vazquez D. Ribosome inactivation by the toxic lectins abrin and ricin. Kinetics of the enzymic activity of the toxin A-chains. Eur J Biochem. 1975;60:281–8. doi: 10.1111/j.1432-1033.1975.tb21001.x. [DOI] [PubMed] [Google Scholar]
- 28.Endo Y, Tsurugi K. The RNA N-glycosidase activity of ricin A-chain. The characteristics of the enzymatic activity of ricin A-chain with ribosomes and with rRNA. J Biol Chem. 1988;263:8735–9. [PubMed] [Google Scholar]
- 29.Peumans WJ, Hao Q, Van Damme EJ. Ribosome-inactivating proteins from plants: more than RNA N-glycosidases? FASEB J. 2001;15:1493–506. doi: 10.1096/fj.00-0751rev. [DOI] [PubMed] [Google Scholar]
- 30.Sandvig K, Grimmer S, Iversen TG, Rodal K, Torgersen ML, Nicoziani P, van Deurs B. Ricin transport into cells: studies of endocytosis and intracellular transport. Int J Med Microbiol. 2000;290:415–20. doi: 10.1016/S1438-4221(00)80055-7. [DOI] [PubMed] [Google Scholar]
- 31.Sandvig K, van Deurs B. Endocytosis, intracellular transport, and cytotoxic action of Shiga toxin and ricin. Physiol Rev. 1996;76:949–66. doi: 10.1152/physrev.1996.76.4.949. [DOI] [PubMed] [Google Scholar]
- 32.van Deurs B, Tønnessen TI, Petersen OW, Sandvig K, Olsnes S. Routing of internalized ricin and ricin conjugates to the Golgi complex. J Cell Biol. 1986;102:37–47. doi: 10.1083/jcb.102.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Sandvig K, Torgersen ML, Engedal N, Skotland T, Iversen T-G. Protein toxins from plants and bacteria: probes for intracellular transport and tools in medicine. FEBS Lett. 2010;584:2626–34. doi: 10.1016/j.febslet.2010.04.008. [DOI] [PubMed] [Google Scholar]
- 34.Sandvig K, van Deurs B. Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin. FEBS Lett. 2002;529:49–53. doi: 10.1016/S0014-5793(02)03182-4. [DOI] [PubMed] [Google Scholar]
- 35.Lord JM, Roberts LM. Toxin entry: retrograde transport through the secretory pathway. J Cell Biol. 1998;140:733–6. doi: 10.1083/jcb.140.4.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Rapak A, Falnes PO, Olsnes S. Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation to cytosol. Proc Natl Acad Sci U S A. 1997;94:3783–8. doi: 10.1073/pnas.94.8.3783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Roberts LM, Smith DC. Ricin: the endoplasmic reticulum connection. Toxicon. 2004;44:469–72. doi: 10.1016/j.toxicon.2004.07.002. [DOI] [PubMed] [Google Scholar]
- 38.Spooner RA, Watson PD, Marsden CJ, Smith DC, Moore KAH, Cook JP, Lord JM, Roberts LM. Protein disulphide-isomerase reduces ricin to its A and B chains in the endoplasmic reticulum. Biochem J. 2004;383:285–93. doi: 10.1042/BJ20040742. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Lord JM, Spooner RA. Ricin trafficking in plant and mammalian cells. Toxins (Basel) 2011;3:787–801. doi: 10.3390/toxins3070787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Griffiths GD, Leek MD, Gee DJ. The toxic plant proteins ricin and abrin induce apoptotic changes in mammalian lymphoid tissues and intestine. J Pathol. 1987;151:221–9. doi: 10.1002/path.1711510310. [DOI] [PubMed] [Google Scholar]
- 41.Narayanan S, Surendranath K, Bora N, Surolia A, Karande AA. Ribosome inactivating proteins and apoptosis. FEBS Lett. 2005;579:1324–31. doi: 10.1016/j.febslet.2005.01.038. [DOI] [PubMed] [Google Scholar]
- 42.Brigotti M, Alfieri R, Sestili P, Bonelli M, Petronini PG, Guidarelli A, Barbieri L, Stirpe F, Sperti S. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 2002;16:365–72. doi: 10.1096/fj.01-0521com. [DOI] [PubMed] [Google Scholar]
- 43.Narayanan S, Surolia A, Karande AA. Ribosome-inactivating protein and apoptosis: abrin causes cell death via mitochondrial pathway in Jurkat cells. Biochem J. 2004;377:233–40. doi: 10.1042/BJ20030797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Sestili P, Alfieri R, Carnicelli D, Martinelli C, Barbieri L, Stirpe F, Bonelli M, Petronini PG, Brigotti M. Shiga toxin 1 and ricin inhibit the repair of H2O2-induced DNA single strand breaks in cultured mammalian cells. DNA Repair (Amst) 2005;4:271–7. doi: 10.1016/j.dnarep.2004.09.007. [DOI] [PubMed] [Google Scholar]
- 45.Hasegawa N, Kimura Y, Oda T, Komatsu N, Muramatsu T. Isolated ricin B-chain-mediated apoptosis in U937 cells. Biosci Biotechnol Biochem. 2000;64:1422–9. doi: 10.1271/bbb.64.1422. [DOI] [PubMed] [Google Scholar]
- 46.Trofa AF, Ueno-Olsen H, Oiwa R, Yoshikawa M. Dr. Kiyoshi Shiga: discoverer of the dysentery bacillus. Clin Infect Dis. 1999;29:1303–6. doi: 10.1086/313437. [DOI] [PubMed] [Google Scholar]
- 47.Keusch GT, Grady GF, Mata LJ, McIver J. The pathogenesis of Shigella diarrhea. I. Enterotoxin production by Shigella dysenteriae I. J Clin Invest. 1972;51:1212–8. doi: 10.1172/JCI106915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun. 1977;18:775–9. doi: 10.1128/iai.18.3.775-779.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.O’Brien AD, LaVeck GD, Thompson MR, Formal SB. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis. 1982;146:763–9. doi: 10.1093/infdis/146.6.763. [DOI] [PubMed] [Google Scholar]
- 50.O’Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science. 1984;226:694–6. doi: 10.1126/science.6387911. [DOI] [PubMed] [Google Scholar]
- 51.O’Brien AO, Lively TA, Chen ME, Rothman SW, Formal SB. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (SHIGA) like cytotoxin. Lancet. 1983;1:702. doi: 10.1016/S0140-6736(83)91987-6. [DOI] [PubMed] [Google Scholar]
- 52.Unkmeir A, Schmidt H. Structural analysis of phage-borne stx genes and their flanking sequences in shiga toxin-producing Escherichia coli and Shigella dysenteriae type 1 strains. Infect Immun. 2000;68:4856–64. doi: 10.1128/IAI.68.9.4856-4864.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Herold S, Karch H, Schmidt H. Shiga toxin-encoding bacteriophages--genomes in motion. Int J Med Microbiol. 2004;294:115–21. doi: 10.1016/j.ijmm.2004.06.023. [DOI] [PubMed] [Google Scholar]
- 54.Johansen BK, Wasteson Y, Granum PE, Brynestad S. Mosaic structure of Shiga-toxin-2-encoding phages isolated from Escherichia coli O157:H7 indicates frequent gene exchange between lambdoid phage genomes. Microbiology. 2001;147:1929–36. doi: 10.1099/00221287-147-7-1929. [DOI] [PubMed] [Google Scholar]
- 55.Gamage SD, Strasser JE, Chalk CL, Weiss AA. Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect Immun. 2003;71:3107–15. doi: 10.1128/IAI.71.6.3107-3115.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Cornick NA, Helgerson AF, Mai V, Ritchie JM, Acheson DWK. In vivo transduction of an Stx-encoding phage in ruminants. Appl Environ Microbiol. 2006;72:5086–8. doi: 10.1128/AEM.00157-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Stein PE, Boodhoo A, Tyrrell GJ, Brunton JL, Read RJ. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature. 1992;355:748–50. doi: 10.1038/355748a0. [DOI] [PubMed] [Google Scholar]
- 58.Fraser ME, Chernaia MM, Kozlov YV, James MN. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol. 1994;1:59–64. doi: 10.1038/nsb0194-59. [DOI] [PubMed] [Google Scholar]
- 59.Donohue-Rolfe A, Keusch GT. Shigella dysenteriae 1 cytotoxin: periplasmic protein releasable by polymyxin B and osmotic shock. Infect Immun. 1983;39:270–4. doi: 10.1128/iai.39.1.270-274.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.De Grandis S, Ginsberg J, Toone M, Climie S, Friesen J, Brunton JL. Nucleotide sequence and promoter mapping of the Escherichia coli Shiga-like toxin operon of bacteriophage H-19B. J Bacteriol. 1987;169:4313–9. doi: 10.1128/jb.169.9.4313-4319.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Strockbine NA, Jackson MP, Sung LM, Holmes RK, O’Brien AD. Cloning and sequencing of the genes for Shiga toxin from Shigella dysenteriae type 1. J Bacteriol. 1988;170:1116–22. doi: 10.1128/jb.170.3.1116-1122.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Jackson MP, Newland JW, Holmes RK, O’Brien AD. Nucleotide sequence analysis of the structural genes for Shiga-like toxin I encoded by bacteriophage 933J from Escherichia coli. Microb Pathog. 1987;2:147–53. doi: 10.1016/0882-4010(87)90106-9. [DOI] [PubMed] [Google Scholar]
- 63.Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem. 1988;171:45–50. doi: 10.1111/j.1432-1033.1988.tb13756.x. [DOI] [PubMed] [Google Scholar]
- 64.Saxena SK, O’Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem. 1989;264:596–601. [PubMed] [Google Scholar]
- 65.Thompson MR, Steinberg MS, Gemski P, Formal SB, Doctor BP. Inhibition of in vitro protein synthesis by Shigella dysenteriae 1 toxin. Biochem Biophys Res Commun. 1976;71:783–8. doi: 10.1016/0006-291X(76)90899-8. [DOI] [PubMed] [Google Scholar]
- 66.Brown JE, Rothman SW, Doctor BP. Inhibition of protein synthesis in intact HeLa cells by Shigella dysenteriae 1 toxin. Infect Immun. 1980;29:98–107. doi: 10.1128/iai.29.1.98-107.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Lindberg AA, Brown JE, Strömberg N, Westling-Ryd M, Schultz JE, Karlsson KA. Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem. 1987;262:1779–85. [PubMed] [Google Scholar]
- 68.Ling H, Boodhoo A, Hazes B, Cummings MD, Armstrong GD, Brunton JL, Read RJ. Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry. 1998;37:1777–88. doi: 10.1021/bi971806n. [DOI] [PubMed] [Google Scholar]
- 69.Waddell T, Cohen A, Lingwood CA. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci U S A. 1990;87:7898–901. doi: 10.1073/pnas.87.20.7898. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Okuda T, Tokuda N, Numata S-I, Ito M, Ohta M, Kawamura K, Wiels J, Urano T, Tajima O, Furukawa K, et al. Targeted disruption of Gb3/CD77 synthase gene resulted in the complete deletion of globo-series glycosphingolipids and loss of sensitivity to verotoxins. J Biol Chem. 2006;281:10230–5. doi: 10.1074/jbc.M600057200. [DOI] [PubMed] [Google Scholar]
- 71.DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem. 1989;264:12520–5. [PubMed] [Google Scholar]
- 72.Donohue-Rolfe A, Acheson DW, Kane AV, Keusch GT. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect Immun. 1989;57:3888–93. doi: 10.1128/iai.57.12.3888-3893.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Bonifacino JS, Rojas R. Retrograde transport from endosomes to the trans-Golgi network. Nat Rev Mol Cell Biol. 2006;7:568–79. doi: 10.1038/nrm1985. [DOI] [PubMed] [Google Scholar]
- 74.Johannes L, Popoff V. Tracing the retrograde route in protein trafficking. Cell. 2008;135:1175–87. doi: 10.1016/j.cell.2008.12.009. [DOI] [PubMed] [Google Scholar]
- 75.Chiron MF, Fryling CM, FitzGerald DJ. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. J Biol Chem. 1994;269:18167–76. [PubMed] [Google Scholar]
- 76.Garred O, van Deurs B, Sandvig K. Furin-induced cleavage and activation of Shiga toxin. J Biol Chem. 1995;270:10817–21. doi: 10.1074/jbc.270.18.10817. [DOI] [PubMed] [Google Scholar]
- 77.Sandvig K, Dubinina E, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B. Protein toxins: mode of action and cell entry. Biochem Soc Trans. 1992;20:724–7. doi: 10.1042/bst0200724. [DOI] [PubMed] [Google Scholar]
- 78.Garred O, Dubinina E, Polesskaya A, Olsnes S, Kozlov J, Sandvig K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J Biol Chem. 1997;272:11414–9. doi: 10.1074/jbc.272.17.11414. [DOI] [PubMed] [Google Scholar]
- 79.LaPointe P, Wei X, Gariépy J. A role for the protease-sensitive loop region of Shiga-like toxin 1 in the retrotranslocation of its A1 domain from the endoplasmic reticulum lumen. J Biol Chem. 2005;280:23310–8. doi: 10.1074/jbc.M414193200. [DOI] [PubMed] [Google Scholar]
- 80.Yu M, Haslam DB. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect Immun. 2005;73:2524–32. doi: 10.1128/IAI.73.4.2524-2532.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Tam PJ, Lingwood CA. Membrane cytosolic translocation of verotoxin A1 subunit in target cells. Microbiology. 2007;153:2700–10. doi: 10.1099/mic.0.2007/006858-0. [DOI] [PubMed] [Google Scholar]
- 82.Tesh VL. Induction of apoptosis by Shiga toxins. Future Microbiol. 2010;5:431–53. doi: 10.2217/fmb.10.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83.Tesh VL. The induction of apoptosis by Shiga toxins and ricin. Curr Top Microbiol Immunol. 2012;357:137–78. doi: 10.1007/82_2011_155. [DOI] [PubMed] [Google Scholar]
- 84.Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, Chen SL, Magun BE. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997;17:3373–81. doi: 10.1128/mcb.17.6.3373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Eisenhauer PB, Chaturvedi P, Fine RE, Ritchie AJ, Pober JS, Cleary TG, Newburg DS. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb3 and sensitivity to Shiga toxin. Infect Immun. 2001;69:1889–94. doi: 10.1128/IAI.69.3.1889-1894.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Lee S-Y, Lee M-S, Cherla RP, Tesh VL. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol. 2008;10:770–80. doi: 10.1111/j.1462-5822.2007.01083.x. [DOI] [PubMed] [Google Scholar]
- 87.Mangeney M, Lingwood CA, Taga S, Caillou B, Tursz T, Wiels J. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993;53:5314–9. [PubMed] [Google Scholar]
- 88.Taga S, Carlier K, Mishal Z, Capoulade C, Mangeney M, Lécluse Y, Coulaud D, Tétaud C, Pritchard LL, Tursz T, et al. Intracellular signaling events in CD77-mediated apoptosis of Burkitt’s lymphoma cells. Blood. 1997;90:2757–67. [PubMed] [Google Scholar]
- 89.Barbieri L, Stirpe F. Ribosome-inactivating proteins from plants: properties and possible uses. Cancer Surv. 1982;1:489–520. [Google Scholar]
- 90.Ishizaki T, Megumi C, Komai F, Masuda K, Oosawa K. Accumulation of a 31-kDa glycoprotein in association with the expression of embryogenic potential by spinach callus in culture. Physiol Plant. 2002;114:109–15. doi: 10.1034/j.1399-3054.2002.1140115.x. [DOI] [PubMed] [Google Scholar]
- 91.Ferreras JM, Barbieri L, Girbés T, Battelli MG, Rojo MA, Arias FJ, Rocher MA, Soriano F, Mendéz E, Stirpe F. Distribution and properties of major ribosome-inactivating proteins (28 S rRNA N-glycosidases) of the plant Saponaria officinalis L. (Caryophyllaceae) Biochim Biophys Acta. 1993;1216:31–42. doi: 10.1016/0167-4781(93)90034-B. [DOI] [PubMed] [Google Scholar]
- 92.Savino C, Federici L, Ippoliti R, Lendaro E, Tsernoglou D. The crystal structure of saporin SO6 from Saponaria officinalis and its interaction with the ribosome. FEBS Lett. 2000;470:239–43. doi: 10.1016/S0014-5793(00)01325-9. [DOI] [PubMed] [Google Scholar]
- 93.Barbieri L, Battelli MG, Stirpe F. Ribosome-inactivating proteins from plants. Biochim Biophys Acta. 1993;1154:237–82. doi: 10.1016/0304-4157(93)90002-6. [DOI] [PubMed] [Google Scholar]
- 94.Bagga S, Seth D, Batra JK. The cytotoxic activity of ribosome-inactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities. J Biol Chem. 2003;278:4813–20. doi: 10.1074/jbc.M207389200. [DOI] [PubMed] [Google Scholar]
- 95.Santanché S, Bellelli A, Brunori M. The unusual stability of saporin, a candidate for the synthesis of immunotoxins. Biochem Biophys Res Commun. 1997;234:129–32. doi: 10.1006/bbrc.1997.6597. [DOI] [PubMed] [Google Scholar]
- 96.Cavallaro U, Nykjaer A, Nielsen M, Soria MR. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. Eur J Biochem. 1995;232:165–71. doi: 10.1111/j.1432-1033.1995.tb20795.x. [DOI] [PubMed] [Google Scholar]
- 97.Weng A, Bachran C, Fuchs H, Melzig MF. Soapwort saponins trigger clathrin-mediated endocytosis of saporin, a type I ribosome-inactivating protein. Chem Biol Interact. 2008;176:204–11. doi: 10.1016/j.cbi.2008.08.004. [DOI] [PubMed] [Google Scholar]
- 98.Vago R, Marsden CJ, Lord JM, Ippoliti R, Flavell DJ, Flavell S-U, Ceriotti A, Fabbrini MS. Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells. FEBS J. 2005;272:4983–95. doi: 10.1111/j.1742-4658.2005.04908.x. [DOI] [PubMed] [Google Scholar]
- 99.Olson BH, Goerner GL. ALPHA SARCIN, A NEW ANTITUMOR AGENT. I. ISOLATION, PURIFICATION, CHEMICAL COMPOSITION, AND THE IDENTITY OF A NEW AMINO ACID. Appl Microbiol. 1965;13:314–21. doi: 10.1128/am.13.3.314-321.1965. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100.Endo Y, Wool IG. Mechanism of Action of Alpha-Sarcin and Eukaryotic Ribosome Structure. Fed Proc. 1982;41:1456. [Google Scholar]
- 101.Martínez-Ruiz A, Kao R, Davies J, Martínez del Pozo A. Ribotoxins are a more widespread group of proteins within the filamentous fungi than previously believed. Toxicon. 1999;37:1549–63. doi: 10.1016/S0041-0101(99)00103-8. [DOI] [PubMed] [Google Scholar]
- 102.Endo Y, Wool IG. The site of action of alpha-sarcin on eukaryotic ribosomes. The sequence at the alpha-sarcin cleavage site in 28 S ribosomal ribonucleic acid. J Biol Chem. 1982;257:9054–60. [PubMed] [Google Scholar]
- 103.Glück A, Endo Y, Wool IG. The ribosomal RNA identity elements for ricin and for alpha-sarcin: mutations in the putative CG pair that closes a GAGA tetraloop. Nucleic Acids Res. 1994;22:321–4. doi: 10.1093/nar/22.3.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 104.Lacadena J, Martínez del Pozo A, Martínez-Ruiz A, Pérez-Cañadillas JM, Bruix M, Mancheño JM, Oñaderra M, Gavilanes JG. Role of histidine-50, glutamic acid-96, and histidine-137 in the ribonucleolytic mechanism of the ribotoxin alpha-sarcin. Proteins. 1999;37:474–84. doi: 10.1002/(SICI)1097-0134(19991115)37:3<474::AID-PROT14>3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
- 105.Masip M, Lacadena J, Mancheño JM, Oñaderra M, Martínez-Ruiz A, Martínez del Pozo A, Gavilanes JG. Arginine 121 is a crucial residue for the specific cytotoxic activity of the ribotoxin alpha-sarcin. Eur J Biochem. 2001;268:6190–6. doi: 10.1046/j.0014-2956.2001.02566.x. [DOI] [PubMed] [Google Scholar]
- 106.Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nat Rev Microbiol. 2006;4:272–82. doi: 10.1038/nrmicro1385. [DOI] [PubMed] [Google Scholar]
- 107.Whitmore A, Krishnaswami CS. An account of the discovery of a hitherto undescribed infective disease occurring among the population of Rangoon. Ind Med Gaz. 1912;47:262–7. [PMC free article] [PubMed] [Google Scholar]
- 108.Holden MTG, Titball RW, Peacock SJ, Cerdeño-Tárraga AM, Atkins T, Crossman LC, Pitt T, Churcher C, Mungall K, Bentley SD, et al. Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. Proc Natl Acad Sci U S A. 2004;101:14240–5. doi: 10.1073/pnas.0403302101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Hautbergue G. [Characterisation of Burkholderia pseudomallei Lethal Factor 1 (BLF1). A breakthrough against melioidosis] Med Sci (Paris) 2012;28:262–4. doi: 10.1051/medsci/2012283011. [DOI] [PubMed] [Google Scholar]
- 110.Wongtrakoongate P, Mongkoldhumrongkul N, Chaijan S, Kamchonwongpaisan S, Tungpradabkul S. Comparative proteomic profiles and the potential markers between Burkholderia pseudomallei and Burkholderia thailandensis. Mol Cell Probes. 2007;21:81–91. doi: 10.1016/j.mcp.2006.08.006. [DOI] [PubMed] [Google Scholar]
- 111.Parsyan A, Svitkin Y, Shahbazian D, Gkogkas C, Lasko P, Merrick WC, Sonenberg N. mRNA helicases: the tacticians of translational control. Nat Rev Mol Cell Biol. 2011;12:235–45. doi: 10.1038/nrm3083. [DOI] [PubMed] [Google Scholar]
- 112.Linder P, Jankowsky E. From unwinding to clamping - the DEAD box RNA helicase family. Nat Rev Mol Cell Biol. 2011;12:505–16. doi: 10.1038/nrm3154. [DOI] [PubMed] [Google Scholar]
- 113.Andreou AZ, Klostermeier D. The DEAD-box helicase eIF4A: paradigm or the odd one out? RNA Biol. 2013;10:19–32. doi: 10.4161/rna.21966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Marintchev A. Roles of helicases in translation initiation: a mechanistic view. Biochim Biophys Acta. 2013;1829:799–809. doi: 10.1016/j.bbagrm.2013.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Augerson WS. A review of the scientific literature as it pertains to Gulf War illnesses. Volume 5: Chemical and Biological Warfare Agents. Rand Corporation 2000; ISBN 0–8330–2680–1. [Google Scholar]
- 116.Gupta RC. Handbook of toxicology of chemical warfare agents. Boston: Academic Press 2009; ISBN 978–0–12–374484–5. [Google Scholar]
- 117.Schep LJ, Temple WA, Butt GA, Beasley MD. Ricin as a weapon of mass terror--separating fact from fiction. Environ Int. 2009;35:1267–71. doi: 10.1016/j.envint.2009.08.004. [DOI] [PubMed] [Google Scholar]
- 118.Griffiths GD. Understanding ricin from a defensive viewpoint. Toxins (Basel) 2011;3:1373–92. doi: 10.3390/toxins3111373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R, Schindler J. A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci U S A. 2006;103:2268–73. doi: 10.1073/pnas.0510893103. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Stone R. Infectious disease. Racing to defuse a bacterial time bomb. Science. 2007;317:1022–4. doi: 10.1126/science.317.5841.1022. [DOI] [PubMed] [Google Scholar]
- 121.Aldhous P. Tropical medicine: melioidosis? Never heard of it. Nature. 2005;434:692–3. doi: 10.1038/434692a. [DOI] [PubMed] [Google Scholar]
- 122.Sprague LD, Neubauer H. Melioidosis in animals: a review on epizootiology, diagnosis and clinical presentation. J Vet Med B Infect Dis Vet Public Health. 2004;51:305–20. doi: 10.1111/j.1439-0450.2004.00797.x. [DOI] [PubMed] [Google Scholar]
- 123.Lee YH, Chen Y, Ouyang X, Gan Y-H. Identification of tomato plant as a novel host model for Burkholderia pseudomallei. BMC Microbiol. 2010;10:28–38. doi: 10.1186/1471-2180-10-28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124.Patel N, Conejero L, De Reynal M, Easton A, Bancroft GJ, Titball RW. Development of vaccines against burkholderia pseudomallei. Front Microbiol. 2011;2:198. doi: 10.3389/fmicb.2011.00198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Neubauer H, Meyer H, Finke EJ. Human glanders. Rev Int Serv Sante Forces Armees. 1997;70:258–65. [Google Scholar]
- 126.Nierman WC, DeShazer D, Kim HS, Tettelin H, Nelson KE, Feldblyum T, Ulrich RL, Ronning CM, Brinkac LM, Daugherty SC, et al. Structural flexibility in the Burkholderia mallei genome. Proc Natl Acad Sci U S A. 2004;101:14246–51. doi: 10.1073/pnas.0403306101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.Sharrer GT. The great glanders epizootic, 1861-1866: a Civil War legacy. Agric Hist. 1995;69:79–97. [PubMed] [Google Scholar]
- 128.Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM., Jr. Biological warfare. A historical perspective. JAMA. 1997;278:412–7. doi: 10.1001/jama.1997.03550050074036. [DOI] [PubMed] [Google Scholar]
- 129.Wheelis M. First shots fired in biological warfare. Nature. 1998;395:213. doi: 10.1038/26089. [DOI] [PubMed] [Google Scholar]
- 130.Fong IW, Alibek K, eds. Bioterrorism and infectious agents: a new dilemma for the 21st century. New York: Springer; 2005. p. 99–145. (Book 4). [Google Scholar]
- 131.Blagden SP, Willis AE. The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol. 2011;8:280–91. doi: 10.1038/nrclinonc.2011.16. [DOI] [PubMed] [Google Scholar]
- 132.Malina A, Cencic R, Pelletier J. Targeting translation dependence in cancer. Oncotarget. 2011;2:76–88. doi: 10.18632/oncotarget.218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blättler WA. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res. 1991;51:6236–42. [PubMed] [Google Scholar]
- 134.Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A. Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphoma. Ann Oncol. 2003;14:729–36. doi: 10.1093/annonc/mdg209. [DOI] [PubMed] [Google Scholar]
- 135.Kuroda K, Liu H, Kim S, Guo M, Navarro V, Bander NH. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate. 2010;70:1286–94. doi: 10.1002/pros.21164. [DOI] [PubMed] [Google Scholar]
- 136.Allen JW, Mantyh PW, Horais K, Tozier N, Rogers SD, Ghilardi JR, Cizkova D, Grafe MR, Richter P, Lappi DA, et al. Safety evaluation of intrathecal substance P-saporin, a targeted neurotoxin, in dogs. Toxicol Sci. 2006;91:286–98. doi: 10.1093/toxsci/kfj143. [DOI] [PubMed] [Google Scholar]
- 137.Li M, Chen Y, Liu Z, Shen F, Bian X, Meng Y. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin (Shanghai) 2009;41:792–9. doi: 10.1093/abbs/gmp068. [DOI] [PubMed] [Google Scholar]
- 138.Wenk GL, Stoehr JD, Quintana G, Mobley S, Wiley RG. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J Neurosci. 1994;14:5986–95. doi: 10.1523/JNEUROSCI.14-10-05986.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Ho M-C, Sturm MB, Almo SC, Schramm VL. Transition state analogues in structures of ricin and saporin ribosome-inactivating proteins. Proc Natl Acad Sci U S A. 2009;106:20276–81. doi: 10.1073/pnas.0911606106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 140.Fraser ME, Cherney MM, Marcato P, Mulvey GL, Armstrong GD, James MNG. Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006;62:627–30. doi: 10.1107/S1744309106021968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Mlsna D, Monzingo AF, Katzin BJ, Ernst S, Robertus JD. Structure of recombinant ricin A chain at 2.3 A. Protein Sci. 1993;2:429–35. doi: 10.1002/pro.5560020315. [DOI] [PMC free article] [PubMed] [Google Scholar]


